Tabelecleucel

N/A

Report date: 2026/02/16 20:01:25

Base Information

Drug NameTabelecleucel
Drug Alias NameEBV targeted T-cell therapy - Atara/MSKCCEpstein-Barrr-virus-specific-cytotoxic-T-lymphocytes-Atara/MSKCCEBV-CTL - Atara/MSKCCEpstein-Barr virus specific cytotoxic T-lymphocytes - Atara/MSKCCEpstein-Barr virus-specific T-cell therapy - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center +[9] 
ClassificationCell and gene therapy > Cell therapy > Source of cells > Blood-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Cytotoxic T-lymphocytes therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsLymphoproliferative DisordersNasopharyngeal NeoplasmsNasopharyngeal Carcinoma +[8] 
Global Approved IndicationsLymphoproliferative Disorders
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2022/12/16
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesAtara Biotherapeutics IncPierre Fabre Medicament
Inactive CompaniesAtara Biotherapeutics Ireland Ltd
Active IndicationsLymphoproliferative DisordersSarcomaLeiomyosarcoma +[5] 
Inactive IndicationsNasopharyngeal NeoplasmsNasopharyngeal CarcinomaViremia

Other Information

ATC CodeN/A
Related LinksN/A